BerGenBio appoints Dr Sue Foden to board
This article was originally published in Scrip
BerGenBio, a Norwegian oncology biopharma company, has appointed Dr Sue Foden to its board of directors. Dr Foden was one of the founders of Cancer Research UK and also served as CEO of Cancer Research Campaign Technology and Cancer Research Ventures. She was an advisor on several EU projects, and is currently a director of Source Bioscience, Elara and Vectura.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.